Marjut Pihlajoki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marjut Pihlajoki has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Markku Heikinheimo
Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, United States; Department of Pediatrics, Center for Child, Adolescent, and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
7 shared publicationsKatja Eloranta
Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Institute for Molecular Medicine Finland, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland
6 shared publications- Markku Heikinheimo
University of Helsinki
5 shared publications - Antti Kyrönlahti
Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
4 shared publications David B. Wilson
Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, United States; Department of Pediatrics, Washington University in St. Louis, St. Louis, United States
4 shared publications- Katja Eloranta
Pediatric Research Center, Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
4 shared publications
Latest Publications
- Open Access
Neuroblastoma immune microenvironment is characterized by limited T cell infiltration and abundant macrophages expressing targetable receptors
Background & Aim Neuroblastoma (NBL) is a heterogenous pediatric malignancy ranging from low-risk infant tumors to high-mortality stage IV disease. We aimed to characterize the composition and spatial organization of the tumor immune microenvironment (TIME) across different tumor stages and assess the prevalence of immunotherapeutic targets, particularly focusing on macrophage-directed therapies. Methods Multiplexed immunofluorescence staining was performed on 185 retrospective formalin-fixed paraffin-embedded tissue cores from 39 NBL patients. Four antibody panels targeting a total of 32 proteins were used. Immune and stromal cell phenotypes and their spatial location were identified by single-cell image analysis and correlated with clinical features such as stage, MYCN status, prior treatment, and survival. Results Immune infiltration varied among samples and patients. CD45+ leukocytes comprised a median of 1.8% of all cells (range 0.2-51.0%, IQR 0.8-6.5%), dominated by tumor-associated macrophages (TAMs; 31.7% of CD45+ cells), and NK cells (15.6%). Stage IV tumors contained fewer lymphocytes. Chemotherapy shifted the TIME toward a macrophage-dominated, lymphocyte-depleted profile. Rather than segregating into M1- and M2-like subsets, TAMs co-expressed pro- and anti-inflammatory markers: CD40, CSF1R, and CD163 were broadly expressed, Clever-1 was detected on 41% of macrophages, and CD200R was virtually absent. CD47+CD45- cells were enriched in stage IV tumors. In univariate Cox analysis, higher fractions of total CD45+, NK, NKT-like, B, and cytotoxic T cells were associated with improved overall survival. Higher proportion of CD47+CD45- cells predicted worse survival. Blood leukocyte counts did not correlate with intratumoral immune infiltration. Conclusions The NBL TIME was heterogenous. High-risk tumors shared a lymphocyte-depleted, myeloid-skewed phenotype, whereas higher overall immune content predicted better survival. Macrophages were present in all tumors and expressed targetable receptors (CD40, CSF1R, CD163, Clever-1). CD47, enriched in high-risk disease, could also be a candidate macrophage-directed target.
Open AccessNeuroblastoma immune microenvironment is characterized by limited T cell infiltration and abundant macrophages expressing targetable receptors
Background & Aim Neuroblastoma (NBL) is a heterogenous pediatric malignancy ranging from low-risk infant tumors to high-mortality stage IV disease. We aimed to characterize the composition and spatial organization of the tumor immune microenvironment (TIME) across different tumor stages and assess the prevalence of immunotherapeutic targets, particularly focusing on macrophage-directed therapies. Methods Multiplexed immunofluorescence staining was performed on 185 retrospective formalin-fixed paraffin-embedded tissue cores from 39 NBL patients. Four antibody panels targeting a total of 32 proteins were used. Immune and stromal cell phenotypes and their spatial location were identified by single-cell image analysis and correlated with clinical features such as stage, MYCN status, prior treatment, and survival. Results Immune infiltration varied among samples and patients. CD45+ leukocytes comprised a median of 1.8% of all cells (range 0.2-51.0%, IQR 0.8-6.5%), dominated by tumor-associated macrophages (TAMs; 31.7% of CD45+ cells), and NK cells (15.6%). Stage IV tumors contained fewer lymphocytes. Chemotherapy shifted the TIME toward a macrophage-dominated, lymphocyte-depleted profile. Rather than segregating into M1- and M2-like subsets, TAMs co-expressed pro- and anti-inflammatory markers: CD40, CSF1R, and CD163 were broadly expressed, Clever-1 was detected on 41% of macrophages, and CD200R was virtually absent. CD47+CD45- cells were enriched in stage IV tumors. In univariate Cox analysis, higher fractions of total CD45+, NK, NKT-like, B, and cytotoxic T cells were associated with improved overall survival. Higher proportion of CD47+CD45- cells predicted worse survival. Blood leukocyte counts did not correlate with intratumoral immune infiltration. Conclusions The NBL TIME was heterogenous. High-risk tumors shared a lymphocyte-depleted, myeloid-skewed phenotype, whereas higher overall immune content predicted better survival. Macrophages were present in all tumors and expressed targetable receptors (CD40, CSF1R, CD163, Clever-1). CD47, enriched in high-risk disease, could also be a candidate macrophage-directed target.
- Open Access
- 10 June 2026
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (9) , 1872-1890
Macrophage Polarization and Spatial Architecture Characterize the Tumor Immune Microenvironment and Prognosis in Hepatoblastoma
- 10 June 2026
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (9) , 1872-1890
Open AccessMacrophage Polarization and Spatial Architecture Characterize the Tumor Immune Microenvironment and Prognosis in Hepatoblastoma
- Open Access
- 11 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0342565
GATA4-targeted compounds induce apoptosis and diminish viability of hepatoblastoma cells
Hepatoblastoma is the most common pediatric liver tumor, and it primarily affects young children. Despite improved treatment results due to modern chemotherapy and advanced surgical techniques, there is urgent need to improve the long-term prognosis of hepatoblastoma patients. Elevated expression of transcription factor GATA4 has been associated with pro-tumorigenic functions in hepatoblastoma. Herein, we explored the effects of a novel series of GATA4-targeted compounds (3i-2010–3i-2014) in several hepatoblastoma cell models. To this end, we assessed cell viability (2D and 3D), caspase 3/7 activity, cell cycle process with automated fluorescence microscopy, and RNA and protein expression using quantitative PCR, RNA-sequencing, and western blotting after treating cells with GATA4-targeted compounds. The GATA4-targeted compounds reduced hepatoblastoma cell viability but affected also healthy control cells when high doses were applied. Out of the five compounds used, the 3i-2012 was the most potent. This compound induced G0/G1 phase cell cycle arrest, increased caspase activity, and resulted in changes in transcriptome of hepatoblastoma cells. The differentially expressed genes (DEGs) were associated with cell cycle regulation. Transcription factor target analysis demonstrated that a notable proportion of DEGs were likely regulated by GATA4. In conclusion, 3i-2012 decreases hepatoblastoma cell survival by disturbing cell cycle regulation in the tumor cells.
- 11 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0342565
Open AccessGATA4-targeted compounds induce apoptosis and diminish viability of hepatoblastoma cells
Hepatoblastoma is the most common pediatric liver tumor, and it primarily affects young children. Despite improved treatment results due to modern chemotherapy and advanced surgical techniques, there is urgent need to improve the long-term prognosis of hepatoblastoma patients. Elevated expression of transcription factor GATA4 has been associated with pro-tumorigenic functions in hepatoblastoma. Herein, we explored the effects of a novel series of GATA4-targeted compounds (3i-2010–3i-2014) in several hepatoblastoma cell models. To this end, we assessed cell viability (2D and 3D), caspase 3/7 activity, cell cycle process with automated fluorescence microscopy, and RNA and protein expression using quantitative PCR, RNA-sequencing, and western blotting after treating cells with GATA4-targeted compounds. The GATA4-targeted compounds reduced hepatoblastoma cell viability but affected also healthy control cells when high doses were applied. Out of the five compounds used, the 3i-2012 was the most potent. This compound induced G0/G1 phase cell cycle arrest, increased caspase activity, and resulted in changes in transcriptome of hepatoblastoma cells. The differentially expressed genes (DEGs) were associated with cell cycle regulation. Transcription factor target analysis demonstrated that a notable proportion of DEGs were likely regulated by GATA4. In conclusion, 3i-2012 decreases hepatoblastoma cell survival by disturbing cell cycle regulation in the tumor cells.
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (12)
Deep learning quantification reveals a fundamental prognostic role for ductular reaction in biliary atresia
Background: We aimed to quantify ductular reaction (DR) in biliary atresia using a neural network in relation to underlying pathophysiology and prognosis. Methods: Image-processing neural network model was applied to 259 cytokeratin-7–stained native liver biopsies of patients with biliary atresia and 43 controls. The model quantified total proportional DR (DR%) composed of portal biliary epithelium (BE%) and parenchymal intermediate hepatocytes (PIH%). The results were related to clinical data, Sirius Red–quantified liver fibrosis, serum biomarkers, and bile acids. Results: In total, 2 biliary atresia biopsies were obtained preoperatively, 116 at Kasai portoenterostomy (KPE) and 141 during post-KPE follow-up. DR% (8.3% vs. 5.9%, p=0.045) and PIH% (1.3% vs. 0.6%, p=0.004) were increased at KPE in patients remaining cholestatic postoperatively. After KPE, patients with subsequent liver transplantation or death showed an increase in DR% (7.9%–9.9%, p = 0.04) and PIH% (1.6%–2.4%, p = 0.009), whereas patients with native liver survival (NLS) showed decreasing BE% (5.5%–3.0%, p = 0.03) and persistently low PIH% (0.9% vs. 1.3%, p = 0.11). In Cox regression, high DR predicted inferior NLS both at KPE [DR% (HR = 1.05, p = 0.01), BE% (HR = 1.05, p = 0.03), and PIH% (HR = 1.13, p = 0.005)] and during follow-up [DR% (HR = 1.08, pp = 0.001), and PIH% (HR = 1.04, p = 0.008)]. DR% correlated with Sirius red–quantified liver fibrosis at KPE (R = 0.47, pR = 0.27, p = 0.004). A close association between DR% and serum bile acids was observed at follow-up (R = 0.61, pp = 0.96) or follow-up (HR = 1.01, p = 0.29). Conclusions: DR predicted NLS in different disease stages before transplantation while associating with serum bile acids after KPE.
- 1 December 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (12)
Open AccessDeep learning quantification reveals a fundamental prognostic role for ductular reaction in biliary atresia
Background: We aimed to quantify ductular reaction (DR) in biliary atresia using a neural network in relation to underlying pathophysiology and prognosis. Methods: Image-processing neural network model was applied to 259 cytokeratin-7–stained native liver biopsies of patients with biliary atresia and 43 controls. The model quantified total proportional DR (DR%) composed of portal biliary epithelium (BE%) and parenchymal intermediate hepatocytes (PIH%). The results were related to clinical data, Sirius Red–quantified liver fibrosis, serum biomarkers, and bile acids. Results: In total, 2 biliary atresia biopsies were obtained preoperatively, 116 at Kasai portoenterostomy (KPE) and 141 during post-KPE follow-up. DR% (8.3% vs. 5.9%, p=0.045) and PIH% (1.3% vs. 0.6%, p=0.004) were increased at KPE in patients remaining cholestatic postoperatively. After KPE, patients with subsequent liver transplantation or death showed an increase in DR% (7.9%–9.9%, p = 0.04) and PIH% (1.6%–2.4%, p = 0.009), whereas patients with native liver survival (NLS) showed decreasing BE% (5.5%–3.0%, p = 0.03) and persistently low PIH% (0.9% vs. 1.3%, p = 0.11). In Cox regression, high DR predicted inferior NLS both at KPE [DR% (HR = 1.05, p = 0.01), BE% (HR = 1.05, p = 0.03), and PIH% (HR = 1.13, p = 0.005)] and during follow-up [DR% (HR = 1.08, pp = 0.001), and PIH% (HR = 1.04, p = 0.008)]. DR% correlated with Sirius red–quantified liver fibrosis at KPE (R = 0.47, pR = 0.27, p = 0.004). A close association between DR% and serum bile acids was observed at follow-up (R = 0.61, pp = 0.96) or follow-up (HR = 1.01, p = 0.29). Conclusions: DR predicted NLS in different disease stages before transplantation while associating with serum bile acids after KPE.
- Open Access
- 25 October 2023
- Published by Elsevier in Advances in Biological Regulation
- Vol. 91, 100997
Biology of childhood hepatoblastoma and the search for novel treatments
- 25 October 2023
- Published by Elsevier in Advances in Biological Regulation
- Vol. 91, 100997
Open AccessBiology of childhood hepatoblastoma and the search for novel treatments
- Open Access
- 26 January 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1118268
SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration
Background: In response to hypoxia, tumor cells undergo transcriptional reprogramming including upregulation of carbonic anhydrase (CA) IX, a metalloenzyme that maintains acid-base balance. CAIX overexpression has been shown to correlate with poor prognosis in various cancers, but the role of this CA isoform in hepatoblastoma (HB) has not been examined.Methods: We surveyed the expression of CAIX in HB specimens and assessed the impact of SLC-0111, a CAIX inhibitor, on cultured HB cells in normoxic and hypoxic conditions.Results: CAIX immunoreactivity was detected in 15 out of 21 archival pathology HB specimens. The CAIX-positive cells clustered in the middle of viable tumor tissue or next to necrotic areas. Tissue expression of CAIX mRNA was associated with metastasis and poor clinical outcome of HB. Hypoxia induced a striking upregulation of CAIX mRNA and protein in three HB cell models: the immortalized human HB cell line HUH6 and patient xenograft-derived lines HB-295 and HB-303. Administration of SLC-0111 abrogated the hypoxia-induced upregulation of CAIX and decreased HB cell viability, both in monolayer and spheroid cultures. In addition, SLC-0111 reduced HB cell motility in a wound healing assay. Transcriptomic changes triggered by SLC-0111 administration differed under normoxic vs. hypoxic conditions, although SLC-0111 elicited upregulation of several tumor suppressor genes under both conditions.Conclusion: Hypoxia induces CAIX expression in HB cells, and the CAIX inhibitor SLC-0111 has in vitro activity against these malignant cells.
- 26 January 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1118268
Open AccessSLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration
Background: In response to hypoxia, tumor cells undergo transcriptional reprogramming including upregulation of carbonic anhydrase (CA) IX, a metalloenzyme that maintains acid-base balance. CAIX overexpression has been shown to correlate with poor prognosis in various cancers, but the role of this CA isoform in hepatoblastoma (HB) has not been examined.Methods: We surveyed the expression of CAIX in HB specimens and assessed the impact of SLC-0111, a CAIX inhibitor, on cultured HB cells in normoxic and hypoxic conditions.Results: CAIX immunoreactivity was detected in 15 out of 21 archival pathology HB specimens. The CAIX-positive cells clustered in the middle of viable tumor tissue or next to necrotic areas. Tissue expression of CAIX mRNA was associated with metastasis and poor clinical outcome of HB. Hypoxia induced a striking upregulation of CAIX mRNA and protein in three HB cell models: the immortalized human HB cell line HUH6 and patient xenograft-derived lines HB-295 and HB-303. Administration of SLC-0111 abrogated the hypoxia-induced upregulation of CAIX and decreased HB cell viability, both in monolayer and spheroid cultures. In addition, SLC-0111 reduced HB cell motility in a wound healing assay. Transcriptomic changes triggered by SLC-0111 administration differed under normoxic vs. hypoxic conditions, although SLC-0111 elicited upregulation of several tumor suppressor genes under both conditions.Conclusion: Hypoxia induces CAIX expression in HB cells, and the CAIX inhibitor SLC-0111 has in vitro activity against these malignant cells.
- Open Access
- 3 January 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , 1263-1273
Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia
Background and Aims: Outcomes after Kasai portoenterostomy (KPE) for biliary atresia remain highly variable for unclear reasons. As reliable early biomarkers predicting KPE outcomes are lacking, we studied the prognostic value of FGF19. Approach and Results: Serum and liver specimens, obtained from biliary atresia patients (N=87) at KPE or age-matched cholestatic controls (N=26) were included. Serum concentration of FGF19 and bile acids, liver mRNA expression of FGF19, and key regulators of bile acid synthesis were related to KPE outcomes and liver histopathology. Immunohistochemistry and in situ hybridization were used for the localization of liver FGF19 expression. Serum levels (223 vs. 61 pg/mL, pp=0.047), and those subsequently underwent liver transplantation (410 vs. 99 pg/mL, p=0.007) had significantly increased serum, but not liver, FGF19, which localized mainly in hepatocytes. In Cox hazard modeling serum FGF19 pp=0.004) or after successful KPE (HR: 6.76, p=0.01). Serum FGF19 correlated positively with increased serum primary bile acids (R=0.41, p=0.004) and ductular reaction (R=0.39, p=0.004). Conclusions: Increased serum FGF19 at KPE predicted inferior long-term native liver survival in biliary atresia and was associated with unsuccessful KPE, elevated serum primary bile acids, and ductular reaction.
- 3 January 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (4) , 1263-1273
Open AccessSerum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia
Background and Aims: Outcomes after Kasai portoenterostomy (KPE) for biliary atresia remain highly variable for unclear reasons. As reliable early biomarkers predicting KPE outcomes are lacking, we studied the prognostic value of FGF19. Approach and Results: Serum and liver specimens, obtained from biliary atresia patients (N=87) at KPE or age-matched cholestatic controls (N=26) were included. Serum concentration of FGF19 and bile acids, liver mRNA expression of FGF19, and key regulators of bile acid synthesis were related to KPE outcomes and liver histopathology. Immunohistochemistry and in situ hybridization were used for the localization of liver FGF19 expression. Serum levels (223 vs. 61 pg/mL, pp=0.047), and those subsequently underwent liver transplantation (410 vs. 99 pg/mL, p=0.007) had significantly increased serum, but not liver, FGF19, which localized mainly in hepatocytes. In Cox hazard modeling serum FGF19 pp=0.004) or after successful KPE (HR: 6.76, p=0.01). Serum FGF19 correlated positively with increased serum primary bile acids (R=0.41, p=0.004) and ductular reaction (R=0.39, p=0.004). Conclusions: Increased serum FGF19 at KPE predicted inferior long-term native liver survival in biliary atresia and was associated with unsuccessful KPE, elevated serum primary bile acids, and ductular reaction.
- Open Access
- 1 February 2022
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 56-57, 101764
Long-term outcomes of biliary atresia patients surviving with their native livers
- 1 February 2022
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 56-57, 101764
Open AccessLong-term outcomes of biliary atresia patients surviving with their native livers
- Open Access
- 28 January 2022
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 44 (2) , 686-698
Analysis of Non-Relapsed and Relapsed Adult Type Granulosa Cell Tumors Suggests Stable Transcriptomes during Tumor Progression
Adult-type granulosa cell tumor (AGCT) is a rare ovarian malignancy characterized by slow growth and hormonal activity. The prognosis of AGCT is generally favorable, but one-third of patients with low-stage disease experience a late relapse, and over half of them die of AGCT. To identify markers that would distinguish patients at risk for relapse, we performed Lexogen QuantSeq 3′ mRNA sequencing on formalin-fixed paraffin-embedded, archival AGCT tissue samples tested positive for the pathognomonic Forkhead Box L2 (FOXL2) mutation. We compared the transcriptomic profiles of 14 non-relapsed archival primary AGCTs (follow-up time 17–26 years after diagnosis) with 13 relapsed primary AGCTs (follow-up time 1.7–18 years) and eight relapsed tumors (follow-up time 2.8–18.9 years). Non-relapsed and relapsed primary AGCTs had similar transcriptomic profiles. In relapsed tumors three genes were differentially expressed: plasmalemma vesicle associated protein (PLVAP) was upregulated (p = 0.01), whereas argininosuccinate synthase 1 (ASS1) (p = 0.01) and perilipin 4 (PLIN4) (p = 0.02) were downregulated. PLVAP upregulation was validated using tissue microarray RNA in situ hybridization. In our patient cohort with extremely long follow-up, we observed similar gene expression patterns in both primary AGCT groups, suggesting that relapse is not driven by transcriptomic changes. These results reinforce earlier findings that molecular markers do not predict AGCT behavior or risk of relapse.
- 28 January 2022
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 44 (2) , 686-698
Open AccessAnalysis of Non-Relapsed and Relapsed Adult Type Granulosa Cell Tumors Suggests Stable Transcriptomes during Tumor Progression
Adult-type granulosa cell tumor (AGCT) is a rare ovarian malignancy characterized by slow growth and hormonal activity. The prognosis of AGCT is generally favorable, but one-third of patients with low-stage disease experience a late relapse, and over half of them die of AGCT. To identify markers that would distinguish patients at risk for relapse, we performed Lexogen QuantSeq 3′ mRNA sequencing on formalin-fixed paraffin-embedded, archival AGCT tissue samples tested positive for the pathognomonic Forkhead Box L2 (FOXL2) mutation. We compared the transcriptomic profiles of 14 non-relapsed archival primary AGCTs (follow-up time 17–26 years after diagnosis) with 13 relapsed primary AGCTs (follow-up time 1.7–18 years) and eight relapsed tumors (follow-up time 2.8–18.9 years). Non-relapsed and relapsed primary AGCTs had similar transcriptomic profiles. In relapsed tumors three genes were differentially expressed: plasmalemma vesicle associated protein (PLVAP) was upregulated (p = 0.01), whereas argininosuccinate synthase 1 (ASS1) (p = 0.01) and perilipin 4 (PLIN4) (p = 0.02) were downregulated. PLVAP upregulation was validated using tissue microarray RNA in situ hybridization. In our patient cohort with extremely long follow-up, we observed similar gene expression patterns in both primary AGCT groups, suggesting that relapse is not driven by transcriptomic changes. These results reinforce earlier findings that molecular markers do not predict AGCT behavior or risk of relapse.
- Open Access
- 22 November 2021
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 9 (1) , 1-15
Neutrophil gelatinase-associated lipocalin does not originate from the kidney during reperfusion in clinical renal transplantation
Background: Acute Kidney Injury (AKI) is a common clinical complication. Plasma/serum neutrophil gelatinase-associated lipocalin (NGAL) has been proposed as a rapid marker of AKI. However, NGAL is not kidney-specific. It exists in three isoforms (monomeric, homo-dimeric and hetero-dimeric). Only the monomeric isoform is produced by renal tubular cells and plasma NGAL levels are confounded by the release of all NGAL isoforms from neutrophils. Our aim was to investigate whether NGAL is released into blood from injured renal tubules. Methods: Kidney transplantation (n = 28) served as a clinical model of renal ischaemic injury. We used ELISA to measure NGAL concentrations at 2 minutes after kidney graft reperfusion in simultaneously taken samples of renal arterial and renal venous blood. Trans-renal gradients (venous–arterial) of NGAL were calculated. We performed Western blotting to distinguish between renal and non-renal NGAL isoforms. Liver-type fatty acid binding protein (LFABP) and heart-type fatty acid binding protein (HFABP) served as positive controls of proximal and distal tubular damage. Results: Significant renal release of LFABP [trans-renal gradient 8.4 (1.7–30.0) ng/ml, p = 0.005] and HFABP [trans-renal gradient 3.7 (1.1–5.0) ng/ml, p = 0.003] at 2 minutes after renal graft reperfusion indicated proximal and distal tubular damage. NGAL concentrations were comparable in renal venous and renal arterial blood. Thus, there was no trans-renal gradient of NGAL. Western blotting revealed that the renal NGAL isoform represented only 6% of the total NGAL in renal venous blood. Conclusions: Ischaemic proximal and distal tubular damage occurs in kidney transplantation without concomitant NGAL washout from the kidney graft into blood. Plasma/serum NGAL levels are confounded by the release of NGAL from neutrophils. Present results do not support the interpretation that increase in plasma NGAL is caused by release from the renal tubules.
- 22 November 2021
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 9 (1) , 1-15
Open AccessNeutrophil gelatinase-associated lipocalin does not originate from the kidney during reperfusion in clinical renal transplantation
Background: Acute Kidney Injury (AKI) is a common clinical complication. Plasma/serum neutrophil gelatinase-associated lipocalin (NGAL) has been proposed as a rapid marker of AKI. However, NGAL is not kidney-specific. It exists in three isoforms (monomeric, homo-dimeric and hetero-dimeric). Only the monomeric isoform is produced by renal tubular cells and plasma NGAL levels are confounded by the release of all NGAL isoforms from neutrophils. Our aim was to investigate whether NGAL is released into blood from injured renal tubules. Methods: Kidney transplantation (n = 28) served as a clinical model of renal ischaemic injury. We used ELISA to measure NGAL concentrations at 2 minutes after kidney graft reperfusion in simultaneously taken samples of renal arterial and renal venous blood. Trans-renal gradients (venous–arterial) of NGAL were calculated. We performed Western blotting to distinguish between renal and non-renal NGAL isoforms. Liver-type fatty acid binding protein (LFABP) and heart-type fatty acid binding protein (HFABP) served as positive controls of proximal and distal tubular damage. Results: Significant renal release of LFABP [trans-renal gradient 8.4 (1.7–30.0) ng/ml, p = 0.005] and HFABP [trans-renal gradient 3.7 (1.1–5.0) ng/ml, p = 0.003] at 2 minutes after renal graft reperfusion indicated proximal and distal tubular damage. NGAL concentrations were comparable in renal venous and renal arterial blood. Thus, there was no trans-renal gradient of NGAL. Western blotting revealed that the renal NGAL isoform represented only 6% of the total NGAL in renal venous blood. Conclusions: Ischaemic proximal and distal tubular damage occurs in kidney transplantation without concomitant NGAL washout from the kidney graft into blood. Plasma/serum NGAL levels are confounded by the release of NGAL from neutrophils. Present results do not support the interpretation that increase in plasma NGAL is caused by release from the renal tubules.